Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Summary

This phase II trial studies how well durvalumab works in treating patients with prostate cancer that is resistant to hormones and has spread to other places in the body. Monoclonal antibodies, such as durvalumab, may interfere with the ability of tumor cells to grow and spread.

Timeline

Start

2018-05-15

Primary completion

2023-05-15

Completion

2023-05-15

Outcome

Outcome not reported

Stopped (Enrollment): “Withdrawn prior to opening to enrollment”

Drugs

Indications